Barbro Linderholm

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Fátima Cardoso, John M.S. Bartlett, Leen Slaets et al. · Annals of Oncology · 2017 · 381 citations · Full text

Eortc 10085/Tbcrc/big/nabcg, Breast Oncology, Medicine +7

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

Barbro Linderholm, Henrik Hellborg, Unn‐Britt Johansson et al. · Annals of Oncology · 2009 · 339 citations

Surgical Oncology, Breast Oncology, Higher Levels +10

Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.

Barbro Linderholm, Björn Tavelin, Kjell Grankvist et al. · Journal of Clinical Oncology · 1998 · 270 citations